Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer
Phase 3 Completed
3,397 enrolled 24 charts
Sorafenib Tosylate, Bevacizumab, Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer
Phase 1 Completed
17 enrolled
Bevacizumab and Cetuximab With or Without Irinotecan in Treating Patients With Irinotecan-Refractory Metastatic Colorectal Cancer
Phase 2 Completed
70 enrolled
Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer
Phase 1/2 Completed
17 enrolled 7 charts
Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer That Progressed During First-Line Therapy
Phase 3 Terminated
72 enrolled 15 charts
Sorafenib, Cetuximab, and Irinotecan in Treating Patients With Advanced or Metastatic Colorectal Cancer
Phase 1 Completed
48 enrolled
Vaccine Therapy and Chemotherapy With or Without Tetanus Toxoid Compared With Chemotherapy Alone in Treating Patients With Metastatic Colorectal Cancer
Phase 2 Unknown
Combination Chemotherapy in Treating Patients With Unresectable Metastatic Colorectal Cancer
Phase 3 Completed
Combination Chemotherapy With or Without SU5416 in Treating Patients With Metastatic Colorectal Cancer
Phase 3 Unknown
Chemotherapy and Internal Radiation in Treating Patients With Colorectal Cancer That Has Spread to the Liver
Phase 2 Unknown
20 enrolled
Study of Tumor Tissue Testing in Selecting Treatment for Patients With Metastatic or Locally Advanced Colorectal Cancer
Phase 2/3 Completed
3,240 enrolled
Combination Chemotherapy in Treating Patients With Stage III Colon Cancer
Phase 3 Completed
1,260 enrolled
7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
Phase 1 Completed
41 enrolled
Combination Chemotherapy Plus Bevacizumab in Treating Patients With Advanced Colorectal Cancer
Phase 2 Completed
Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas
Phase 1 Completed
24 enrolled
ZD 1839 Plus Combination Chemotherapy in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Colorectal Cancer
Phase 1 Completed
22 enrolled
Monoclonal Antibody Plus Chemotherapy in Treating Patients With Advanced Colorectal Cancer That Overexpresses HER2
Phase 2 Completed
32 enrolled
SU5416 and Irinotecan in Treating Patients With Advanced Colorectal Cancer
Phase 1/2 Completed
68 enrolled
Gefitinib and Combination Chemotherapy in Treating Patients With Advanced or Recurrent Colorectal Cancer
Phase 2 Terminated
50 enrolled
Chemotherapy With or Without Isolated Hepatic Perfusion With Melphalan in Treating Patients With Colorectal Cancer That Has Spread to the Liver
Phase 3 Completed
Bevacizumab and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
Phase 2 Unknown
47 enrolled
Cetuximab and Combination Chemotherapy in Treating Patients With Advanced or Metastatic Colorectal Cancer
Phase 2 Completed
80 enrolled
Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer With Liver Metastases or Lung Metastases That Are Potentially Removable by Surgery
Phase 2 Unknown
35 enrolled
Fluorouracil and Irinotecan With or Without Leucovorin Compared With Observation in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer
Phase 3 Unknown
1,976 enrolled
Combination Chemotherapy in Treating Patients With Recurrent Metastatic Colorectal Cancer
Phase 3 Unknown
109 enrolled
Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
Phase 2 Unknown
Fluorouracil, Leucovorin, and Irinotecan in Treating Patients With Recurrent or Refractory Metastatic Unresectable Colorectal Cancer
Phase 2 Unknown
Irinotecan With or Without Capecitabine as Second-Line Therapy in Treating Older Patients With Progressive, Metastatic Colorectal Cancer That Cannot Be Removed By Surgery
Phase 2 Unknown
78 enrolled